An amino acid mutation(R127→I) in the 3A non-structural protein of an FMDV serotype Asia1 rabbit-attenuated ZB strain was previously found after attenuation of the virus. To explore the effects of this mutation on vi...An amino acid mutation(R127→I) in the 3A non-structural protein of an FMDV serotype Asia1 rabbit-attenuated ZB strain was previously found after attenuation of the virus. To explore the effects of this mutation on viral replication and infection, the amino acid residue isoleucine(I) was changed to arginine(R) in the infectious cDNA clone of the rabbit-attenuated ZB strain by sitedirected mutagenesis, and the R127-mutated virus was rescued. BHK monolayer cells and suckling mice were inoculated with the R127-mutated virus to test its growth property and pathogenicity, respectively. The effects of the R127 mutation on viral replication and virulence were analyzed. The data showed that there was a slight difference in plaque morphology between the R127-mutated and wild-type viruses. The growth rate of the mutated virus was lower in BHK-21 cells and its virulence in suckling mice was also attenuated. This study indicates that the R127 mutation in 3A may play an important role in FMDV replication in vitro and in pathogenicity in suckling mice.展开更多
目的:观察茵陈贞芪六君子汤加减联合恩替卡韦治疗慢性乙型肝炎肝硬化的效果及对肝功能、病毒复制能力的影响。方法:选取2016年2月~2019年12月就诊于我院的慢性乙型肝炎肝硬化患者85例,根据其治疗方法不同,分为观察组(n=43)和对照组(n=42...目的:观察茵陈贞芪六君子汤加减联合恩替卡韦治疗慢性乙型肝炎肝硬化的效果及对肝功能、病毒复制能力的影响。方法:选取2016年2月~2019年12月就诊于我院的慢性乙型肝炎肝硬化患者85例,根据其治疗方法不同,分为观察组(n=43)和对照组(n=42)。对照组采用恩替卡韦治疗,观察组在其基础上采用茵陈贞芪六君子汤加减治疗,连续治疗12w。比较两组临床疗效;检测并比较两组治疗前后谷丙转氨酶(AlanineAminotransferase,ALT)、谷草转氨酶(Aspartate Aminotransferase,AST)、总胆红素(Total Bilirubin,TBIL)、直接胆红素(Direct Bilirubin,DBIL)水平;检测并比较治疗12w后两组乙肝病毒-脱氧核糖核酸(Hepatitis B Virus-Deoxyribonucleic Acid,HBV-DNA)、乙型肝炎e抗原(Hepatitis B e-Antigen,HBeAg)变化情况。结果:治疗12w后,观察组临床总有效率(95.35%)显著高于对照组(80.95%),差异有统计学意义(P<0.05);治疗12w后,与对照组相比,观察组ALT、AST、TBIL、DBIL水平显著降低,差异有统计学意义(P<0.05);治疗12w后,与对照组相比,观察组HBV-DNA转阴率(97.67%)和HBeAg转阴率(65.12%)显著升高,差异有统计学意义(P<0.05)。结论:茵陈贞芪六君子汤加减联合恩替卡韦治疗慢性乙型肝炎肝硬化能够明显提高其临床疗效,改善肝功能,抑制病毒复制能力。展开更多
基金jointly supported by grants from National Natural Science Foundation of China(No.31060343)Innovative Talents in Science and Technology Project of Yunnan Province(2011HB035)
文摘An amino acid mutation(R127→I) in the 3A non-structural protein of an FMDV serotype Asia1 rabbit-attenuated ZB strain was previously found after attenuation of the virus. To explore the effects of this mutation on viral replication and infection, the amino acid residue isoleucine(I) was changed to arginine(R) in the infectious cDNA clone of the rabbit-attenuated ZB strain by sitedirected mutagenesis, and the R127-mutated virus was rescued. BHK monolayer cells and suckling mice were inoculated with the R127-mutated virus to test its growth property and pathogenicity, respectively. The effects of the R127 mutation on viral replication and virulence were analyzed. The data showed that there was a slight difference in plaque morphology between the R127-mutated and wild-type viruses. The growth rate of the mutated virus was lower in BHK-21 cells and its virulence in suckling mice was also attenuated. This study indicates that the R127 mutation in 3A may play an important role in FMDV replication in vitro and in pathogenicity in suckling mice.
文摘目的:观察茵陈贞芪六君子汤加减联合恩替卡韦治疗慢性乙型肝炎肝硬化的效果及对肝功能、病毒复制能力的影响。方法:选取2016年2月~2019年12月就诊于我院的慢性乙型肝炎肝硬化患者85例,根据其治疗方法不同,分为观察组(n=43)和对照组(n=42)。对照组采用恩替卡韦治疗,观察组在其基础上采用茵陈贞芪六君子汤加减治疗,连续治疗12w。比较两组临床疗效;检测并比较两组治疗前后谷丙转氨酶(AlanineAminotransferase,ALT)、谷草转氨酶(Aspartate Aminotransferase,AST)、总胆红素(Total Bilirubin,TBIL)、直接胆红素(Direct Bilirubin,DBIL)水平;检测并比较治疗12w后两组乙肝病毒-脱氧核糖核酸(Hepatitis B Virus-Deoxyribonucleic Acid,HBV-DNA)、乙型肝炎e抗原(Hepatitis B e-Antigen,HBeAg)变化情况。结果:治疗12w后,观察组临床总有效率(95.35%)显著高于对照组(80.95%),差异有统计学意义(P<0.05);治疗12w后,与对照组相比,观察组ALT、AST、TBIL、DBIL水平显著降低,差异有统计学意义(P<0.05);治疗12w后,与对照组相比,观察组HBV-DNA转阴率(97.67%)和HBeAg转阴率(65.12%)显著升高,差异有统计学意义(P<0.05)。结论:茵陈贞芪六君子汤加减联合恩替卡韦治疗慢性乙型肝炎肝硬化能够明显提高其临床疗效,改善肝功能,抑制病毒复制能力。
